France Molecular Forensics Market Size & Outlook, 2026-2034
France Molecular Forensics Market Insights
- As per Reed Intelligence insights, the France Molecular Forensics Market stood at USD 393.8 Million in 2025 and is anticipated to grow to USD 983.66 Million by 2034.
- The France market is expected to advance at a CAGR of 10.65% from 2026 through 2034.
- In 2025, PCR-Based Analysis accounted for the highest share of the Technology market size.
- During the forecast period, Next-Generation Sequencing is set to register the highest growth, making it the most lucrative Technology segment.
![France Molecular Forensics Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/france-molecular-forensics-market-france-technology-130986.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, France held 4.68% of the global Molecular Forensics Market size.
- By 2034, United States is anticipated to capture the largest share of the global Molecular Forensics Market.
- In Europe, Germany is expected to lead the regional Molecular Forensics Market size by 2034.
- France will remain the fastest-growing market in Europe, reaching USD 979.13 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 393.8 Million |
| Market Size In 2034 | USD 983.66 Million |
| Largest segment | PCR-Based Analysis |
| Units | Revenue in USD Million |
| CAGR | 10.65% (2026-2034) |
| Segmnetation Covered | |
| Technology |
|
| Application |
|
| End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Molecular Forensics Market Technology 2026-2034 (USD Million)
| Technology | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCR-Based Analysis | XX.x | XX.x | XX.x | 159.06 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Next-Generation Sequencing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capillary Electrophoresis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Microarray Technology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Molecular Forensics Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Criminal Investigation | XX.x | XX.x | XX.x | 169.73 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Paternity Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biodefense and Pathogen Tracing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Food Authentication | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Wildlife Forensics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Molecular Forensics Market End Use 2026-2034 (USD Million)
| End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Government Forensic Laboratories | XX.x | XX.x | XX.x | 196.82 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Private Forensic Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Academic and Research Institutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Healthcare and Biosurveillance Agencies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.